Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01290471 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01290471 is a Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 36 participants.
The verdict
NCT01290471, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a Phase 1, open label study to assess the safety and tolerability of U3 1565, determine maximum tolerated dose (MTD) or establish maximum administered dose (MAD) safety and tolerability.
Interventions
- DRUG U3-1565
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2011-01 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01290471
The ClinicalTrials.gov registry entry for NCT01290471 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which U3-1565 is the first listed.
NCT01290471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01290471 about?
NCT01290471 is a clinical study titled "Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors". This is a Phase 1, open label study to assess the safety and tolerability of U3 1565, determine maximum tolerated dose (MTD) or establish maximum administered dose (MAD) safety and tolerability.
What is the current status of trial NCT01290471?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2011-01. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01290471?
The interventions under investigation include: U3-1565 (DRUG).
Who is sponsoring clinical trial NCT01290471?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.